Literature DB >> 378624

The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis.

R Carlisle, J T Galambos, W D Warren.   

Abstract

Thirty patients with cirrhosis were evaluated with the 2-hr [14C]aminopyrine breath test (score) and with conventional liver tests. Of the 30 patients, 24 also had current liver biopsies. There was a good correlation between necroinflammatory activity in the 24 cirrhotic liver biopsies and the 2-hr aminopyrine scores. All five patients who had at least grade 2 necroinflammatory activity on their biopsy had an abnormal prothrombin time (greater than 3.5 sec above control) and their aminopyrine score was less than 2%. The correlation was good between the 2-hr aminopyrine score and the prothrombin time (seconds over control). No correlation was found between the 2-hr aminopyrine score and either the serum aspartate aminotransferase (SGOT) or any other liver test except for the prothrombin time. It seems that the 2-hr aminopyrine score and prothrombin time are more likely to give a quantitative estimate of total functioning parenchymal mass which is left unaffected by hepatocellular disease in cirrhosis, than the other commonly used liver tests.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378624     DOI: 10.1007/bf01297121

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

2.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

3.  Kinetics of CO2-HCO3 minus in normal adult males.

Authors:  H S Winchell; H Stahelin; N Kusubov; B Slanger; M Fish; M Pollycove; J H Lawrence
Journal:  J Nucl Med       Date:  1970-12       Impact factor: 10.057

4.  Relationship between 505 paired liver tests and biopsies in 242 obese patients.

Authors:  J T Galambos; C E Wills
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

5.  Selective and total shunts in the treatment of bleeding varices. A randomized controlled trial.

Authors:  J T Galambos; W D Warren; D Rudman; R B Smith; A A Salam
Journal:  N Engl J Med       Date:  1976-11-11       Impact factor: 91.245

6.  Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.

Authors:  G W Hepner; E S Vesell
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

7.  Dose dependence of the 14C-aminopyrine breath test. Intrasubject comparison of tracer and pharmacological doses.

Authors:  I Gikalov; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

8.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects.

Authors:  D Rudman; T J DiFulco; J T Galambos; R B Smith; A A Salam; W D Warren
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

View more
  14 in total

1.  Influence of low-dose oral contraceptives, alcohol, and grapefruit on.

Authors:  H Van Vlierberghe; F Van Durme; H Verdievel; M Dhont; M de Vos; A Elewaut
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

2.  Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.

Authors:  W L Chuang; H W Liu; W Y Chang; S C Chen; M Y Hsieh; L Y Wang
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

3.  Effect of liver disease on the kinetics of lactate removal after heavy exercise.

Authors:  R Casaburi; S Oi
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

4.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

5.  Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.

Authors:  Edoardo G Giannini; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

6.  Abnormal aminopyrine metabolism in patients with chronic hepatitis.

Authors:  G W Hepner; E Piken; J Lechago
Journal:  West J Med       Date:  1981-05

7.  High serum levels of secretory IgA in liver disease: possible liver origin of the circulating secretory component.

Authors:  D L Delacroix; M Reynaert; S Pauwels; A P Geubel; J P Vaerman
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

8.  Plasma free amino acid pattern in chronic hepatitis as a sensitive and prognostic index.

Authors:  T Kano; M Nagaki; T Takahashi; H Ohnishi; K Saitoh; K Kimura; Y Muto
Journal:  Gastroenterol Jpn       Date:  1991-06

9.  Perfused Kupffer cell mass. Correlation with histology and severity of chronic liver disease.

Authors:  J Hoefs; K Chang; F Wang; G Kanel; T Morgan; P Braunstein
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

10.  [13C]Aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives.

Authors:  A R Opekun; P D Klein; D Y Graham
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.